ICLRN Stock Chart & Stats
$1850.00
$0.00(0.00%)
At close: 4:00 PM EDT
$1850.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$1,850.00 - $3,290.00
Previous CloseN/A
Volume0.00
Average Volume (3M)11.00
Market Cap
$308.37B
Enterprise Value$15.86B
Total Cash (Recent Filing)$808.98M
Total Debt (Recent Filing)$3.51B
Price to Earnings (P/E)49.9
Beta0.16
Next Earnings
Feb 24, 2027EPS Estimate
52.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.85
Shares Outstanding77,154,205
10 Day Avg. Volume0
30 Day Avg. Volume11
Financial Highlights & Ratios
PEG Ratio-0.90
Price to Book (P/B)1.55
Price to Sales (P/S)1.73
P/FCF Ratio16.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$4,157.10Price Target Upside124.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)197.38
Revenue Forecast (FY)$152.03B
Bulls Say, Bears Say
Bulls Say
Record Bookings And BacklogRecord bookings and sustained book-to-bill above 1.3x indicate strong sponsor demand and support backlog conversion into future revenue. Continued wins across large pharma, midsized companies, and biotech can reinforce ICON’s market position and improve medium-term growth visibility.
Strong Cash GenerationRobust operating and free cash flow gives ICON internal funding for technology, therapeutic capabilities, selective acquisitions, debt service, and shareholder returns. Cash conversion that broadly supports earnings strengthens resilience and reduces reliance on external financing.
Technology-led ProductivityMeasured productivity gains from AI and digital tools can improve delivery capacity, reduce labor intensity, and support margins as trial complexity grows. Embedding these platforms across services may also deepen client relationships and create a durable operating advantage.
Bears Say
Persistent Revenue PressureRecent revenue contraction shows that strong bookings have not yet translated into comparable top-line growth. The decline, including the effect of the Symphony divestiture, raises execution risk around backlog conversion and leaves near-term growth dependent on renewed demand and delivery.
Margin CompressionLower operating and EBITDA margins indicate that profitability has not yet returned to prior levels despite recent sequential improvement. Sustained compression would reduce earnings conversion from revenue, constrain reinvestment capacity, and make results more sensitive to mix and execution.
Pass-through Revenue VolatilityA pass-through mix near one-third makes reported revenue more volatile and less representative of underlying fee growth, while typically providing lower-margin economics than core services. This complicates forecasting and can obscure the pace of durable operating expansion.
Icon News
ICLRN FAQ
What was Icon plc’s price range in the past 12 months?
Icon plc lowest stock price was $1850.00 and its highest was $3290.00 in the past 12 months.
What is Icon plc’s market cap?
Icon plc’s market cap is $308.37B.
When is Icon plc’s upcoming earnings report date?
Icon plc’s upcoming earnings report date is Feb 24, 2027 which is in 117 days.
How were Icon plc’s earnings last quarter?
Icon plc released its earnings results on Oct 27, 2026. The company reported $49.643 earnings per share for the quarter, beating the consensus estimate of $48.84 by $0.802.
Is Icon plc overvalued?
According to Wall Street analysts Icon plc’s price is currently Undervalued.
Does Icon plc pay dividends?
Icon plc does not currently pay dividends.
What is Icon plc’s EPS estimate?
Icon plc’s EPS estimate is 52.72.
How many shares outstanding does Icon plc have?
Icon plc has 77,154,205 shares outstanding.
What happened to Icon plc’s price movement after its last earnings report?
Icon plc reported an EPS of $49.643 in its last earnings report, beating expectations of $48.84. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Icon plc?
Currently, no hedge funds are holding shares in MX:ICLRN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Icon Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4,157.10 (124.71% Upside)
$4,157.10 (124.71% Upside)
Blogger Sentiment
Bullish
MX:ICLRN Sentiment 83%
Sector Average 65%
Sector Average 65%
Insider Transactions
Sold Shares
Worth $43.4M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
20.49%
12-Months-Change
Fundamentals
Return on Equity
4.85%
Trailing 12-Months
Asset Growth
0.52%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Icon plc
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
ICLRN Company Deck
ICLRN Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was strongly positive overall. Commercial momentum, record net bookings, sustained book-to-bill performance, margin expansion, cost discipline, cash generation, technology productivity gains, and constructive demand outweighed the year-over-year revenue decline, pass-through volatility, foreign exchange headwind, and expected fourth-quarter SG&A increase.View all MX:ICLRN earnings summariesICLRN Stock 12 Month Forecast
Average Price Target
$4,157.10
▲(124.71% Upside)
Technical Analysis
Charles River Labs
―
Labcorp Holdings
―
Thermo Fisher
―
IQVIA Holdings
―
Medpace Holdings
―